Hutter Gregor, von Felten Stefanie, Sailer Martin H, Schulz Marianne, Mariani Luigi
Neurosurgical Department and.
J Neurosurg. 2014 Sep;121(3):735-44. doi: 10.3171/2014.6.JNS131917. Epub 2014 Jul 18.
Cerebrospinal fluid leakage is an immanent risk of cranial surgery with dural opening. Recognizing the risk factors for this complication and improving the technique of dural closure may reduce the associated morbidity and its surgical burden. The aim of this paper was to investigate whether the addition of TachoSil on top of the dural suture reduces postoperative CSF leakage compared with dural suturing alone and to assess the frequency and risk factors for dural leakage and potentially related complications after elective craniotomy.
The authors conducted a prospective, randomized, double-blinded single-center trial in patients undergoing elective craniotomy with dural opening. They compared their standard dural closure by running suture alone (with the use of a dural patch if needed) to the same closure with the addition of TachoSil on top of the suture. The primary end point was the incidence of CSF leakage, defined as CSF collection or any open CSF fistula within 30 days. Secondary end points were the incidence of infection, surgical revision, and length of stay in the intensive care unit (ICU) or intermediate care (IMC) unit. The site of craniotomy, a history of diabetes mellitus, a diagnosis of meningioma, the intraoperative need of a suturable dural substitute, and blood parameters were assessed as potential risk factors for CSF leakage.
The authors enrolled 241 patients, of whom 229 were included in the analysis. Cerebrospinal fluid leakage, mostly self-limiting subgaleal collections, occurred in 13.5% of patients. Invasive treatment was performed in 8 patients (3.5%) (subgaleal puncture in 6, lumbar drainage in 1, and surgical revision in 1 patient). Diabetes mellitus, a higher preoperative level of C-reactive protein (CRP), and the intraoperative need for a dural patch were positively associated with the occurrence of the primary end point (p = 0.014, 0.01, and 0.049, respectively). Cerebrospinal fluid leakage (9.7% vs 17.2%, OR 0.53 [95% CI 0.23-1.15], p = 0.108) and infection (OR 0.18 [95% CI 0.01-1.18], p = 0.077) occurred less frequently in the study group than in the control group. TachoSil significantly reduced the probability of staying in the IMC unit for 1 day or longer (OR 0.53 [95% CI 0.27-0.99], p = 0.048). Postoperative epidural hematoma and empyema occurred in the control group but not in the study group.
Dural leakage after elective craniotomy/durotomy occurs more frequently in association with diabetes mellitus, elevated preoperative CRP levels, and the intraoperative need of a dural patch. This randomized controlled trial showed no statistically significant reduction of postoperative CSF leakage and surgical site infections upon addition of TachoSil on the dural suture, but there was a significant reduction in the length of stay in the IMC unit. Dural augmentation with TachoSil was safe and not related to adverse events. Clinical trial registration no. NCT00999999 ( http://www.ClinicalTrials.gov ).
脑脊液漏是开颅硬膜切开手术固有的风险。识别该并发症的危险因素并改进硬膜缝合技术可能会降低相关的发病率及其手术负担。本文的目的是研究在硬膜缝合基础上加用速即纱(TachoSil)与单纯硬膜缝合相比是否能减少术后脑脊液漏,并评估择期开颅术后硬膜漏及其潜在相关并发症的发生率和危险因素。
作者对接受择期开颅硬膜切开手术的患者进行了一项前瞻性、随机、双盲单中心试验。他们将单纯连续缝合(必要时使用硬膜补片)的标准硬膜闭合方法与在缝合基础上加用速即纱的相同闭合方法进行比较。主要终点是脑脊液漏的发生率,定义为30天内脑脊液聚集或任何开放性脑脊液瘘。次要终点是感染、手术翻修以及重症监护病房(ICU)或中级护理(IMC)病房的住院时间。开颅部位、糖尿病史、脑膜瘤诊断、术中对可缝合硬膜替代物的需求以及血液参数被评估为脑脊液漏的潜在危险因素。
作者纳入了241例患者,其中229例纳入分析。脑脊液漏大多为自限性帽状腱膜下积液,发生率为13.5%。8例患者(3.5%)接受了侵入性治疗(6例进行帽状腱膜下穿刺,1例进行腰椎引流,1例进行手术翻修)。糖尿病、术前较高的C反应蛋白(CRP)水平以及术中对硬膜补片的需求与主要终点的发生呈正相关(分别为p = 0.014、0.01和0.049)。研究组脑脊液漏(9.7%对17.2%,OR 0.53 [95% CI 0.23 - 1.15],p = 0.108)和感染(OR 0.18 [95% CI 0.01 - 1.18],p = 0.077)的发生率低于对照组。速即纱显著降低了在IMC病房住院1天或更长时间的概率(OR 0.53 [95% CI 0.27 - 0.99],p = 0.048)。对照组发生了术后硬膜外血肿和积脓,而研究组未发生。
择期开颅/硬膜切开术后硬膜漏更常与糖尿病、术前CRP水平升高以及术中对硬膜补片的需求相关。这项随机对照试验表明,在硬膜缝合上加用速即纱并没有使术后脑脊液漏和手术部位感染有统计学意义的显著减少,但IMC病房的住院时间显著缩短。用速即纱进行硬膜增强是安全的,且与不良事件无关。临床试验注册号:NCT00999999(http://www.ClinicalTrials.gov)